Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) – Analysts at HC Wainwright reduced their Q3 2026 earnings estimates for shares of Sana Biotechnology in a research note issued to investors on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.14) for the quarter, down from their previous estimate of ($0.13). The consensus estimate for Sana Biotechnology’s current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Sana Biotechnology’s Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.54) EPS, FY2028 earnings at ($0.62) EPS, FY2029 earnings at ($0.62) EPS and FY2030 earnings at ($0.45) EPS.
A number of other research firms have also commented on SANA. Wall Street Zen lowered shares of Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. Rodman & Renshaw began coverage on Sana Biotechnology in a report on Monday, May 11th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, Weiss Ratings upgraded shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.
Sana Biotechnology Trading Down 0.5%
Shares of Sana Biotechnology stock opened at $3.77 on Thursday. The company’s 50-day moving average price is $3.33 and its 200-day moving average price is $3.46. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -4.96 and a beta of 2.16. Sana Biotechnology has a 12-month low of $2.61 and a 12-month high of $6.55.
Sana Biotechnology (NASDAQ:SANA – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Xponance LLC lifted its stake in shares of Sana Biotechnology by 25.6% in the 4th quarter. Xponance LLC now owns 13,068 shares of the company’s stock valued at $53,000 after acquiring an additional 2,662 shares during the last quarter. Creative Planning grew its position in Sana Biotechnology by 5.3% during the 3rd quarter. Creative Planning now owns 54,177 shares of the company’s stock worth $192,000 after acquiring an additional 2,719 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Sana Biotechnology by 29.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,944 shares of the company’s stock worth $53,000 after acquiring an additional 2,943 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in Sana Biotechnology by 74.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after purchasing an additional 4,088 shares during the period. Finally, Polymer Capital Management US LLC increased its stake in Sana Biotechnology by 32.5% in the 4th quarter. Polymer Capital Management US LLC now owns 18,285 shares of the company’s stock worth $74,000 after purchasing an additional 4,480 shares during the period. 88.23% of the stock is owned by hedge funds and other institutional investors.
Sana Biotechnology Company Profile
Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.
The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.
Read More
- Five stocks we like better than Sana Biotechnology
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
